| Name | Title | Contact Details |
|---|
Norwood Medical is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Assure Neuromonitoring is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. While Assure focuses primarily on supporting spinal and vascular surgeries, plans are in place to support other classes of medicine that rely on the standard of care that intraoperative neuromonitoring provides. Assure Neuromonitoring is accredited by The Joint Commission and committed to delivering the highest quality service in the industry. Our patient driven focus is at the core of our organization and is impressed upon all stakeholders. Assure employs the highest quality technologists and support staff in the field, thus instilling continuity, reliability and confidence for both patients and physicians alike.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
Qvella is a molecular diagnostics company with the goal of dramatically reducing time to results in bacteriology. The company has developed a highly differentiated technology for pathogen detection by direct sampling of boldily fluids without the need for culturing or time consuming sample processing.
Viaflo is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.